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Abstract
Background: Genotype I (GI) Japanese encephalitis virus (JEV) that replaced GIII virus has become the dominant circulating
virus in Asia. Currently, all registered live and inactivated JEV vaccines are derived from genotype III viruses. In Taiwan, the
compulsory JEV vaccination policy recommends that children receives four doses of formalin-inactivated Nakayama (GIII)
JEV vaccine.
Methodology/Principal Findings: To evaluate the influence of genotype replacement on the post-vaccination viral
neutralizing ability by GIII and GI viruses, the small panel of vaccinated-children serum specimens was assembled, and the
reciprocal 50% plaque-reduction neutralizing antibody titers (PRNT50) were measured against Nakayama vaccine strain, CJN
GIII human brain isolate and TC2009-1 GI mosquito isolate. The seropositivity rate (PRNT50$1:10) and geometric mean titers
(GMT) against the TC2009-1 virus were the lowest among the three viruses. The protective threshold against the CJN and
TC2009-1 viruses could only be achieved when the GMT against Nakayama virus was $1:20 or $1:80, respectively. Using
undiluted vaccinees’ sera, the enhancement of JEV infection in K562 cells was observed in some low or non-neutralizing
serum specimens.
Conclusions/Significance: Our preliminary study has shown that neutralizing antibodies, elicited by the mouse brain-
derived and formalin-inactivated JEV Nakayama vaccine among a limited number of vaccinees, have reduced neutralizing
capacity against circulating GI virus, but more detailed studies are needed to address the potential impact on the future
vaccine policy.
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Introduction
South and Southeast Asia are Japanese encephalitis (JE) endemic
areas in which approximately 10% of the susceptible populations
are infected with JE virus (JEV) each year, based on the ratio of
asymptomatic to symptomatic infections of 200 to 1 [1,2,3]. The
most cost-effective control strategy for JE is vaccination, and there
are several licensed vaccines, including live-attenuated, chimeric
live-attenuated and inactivated SA14-14-2; inactivated Nakayama;
P3 and Beijing-1 vaccines [3,4,5,6]. In Taiwan, compulsory
vaccination has been implemented since 1968 using the mouse-
brain derived and formalin-inactivated Nakayama vaccine, and
since then clinical JE cases have decreased dramatically to 20–30
cases each year [7]. It has been estimated that vaccine effectiveness
is in the range of 85% to 90% after immunization with two doses of
inactivated Nakayama vaccine [7,8].
We have witnessed dramatic changes in the molecular
epidemiology of circulating JEV in the past two decades.
Historically, genotype III (GIII) viruses were the most widely
distributed JEV in South and Southeast Asia [9]. However,
genotype I (GI) JEV, having emerged in the 1970s in Thailand/
Cambodia, has replaced GIII as the dominant circulating virus in
JE endemic/epidemic regions since the 1990s [10]. Genotype I
viruses first appeared in Japan, and by the 1990s the majority of
Japanese JEV isolates belonged to GI [11]. Subsequently, the
phenomena of genotype replacement were observed in many
countries, including Korea, Vietnam, Thailand, and China
[12,13,14]. Genotype I JEV was first detected in Taiwan in
2008, and became the dominant circulating genotype island-wide
within a year [15,16].
The nucleotide and amino acid variation between the envelope
(E) glycoproteins of GIII and GI JEV is in approximately 12% and
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3%, respectively [9]. All licensed JEV vaccine strains, including
SA14-14-2, Nakayama, P3, and Beijing-1, belong to GIII. The
reduced capacity of neutralizing antibody against field-isolated
GIII viruses had been reported among vaccinated human serum
samples [17,18]. Thus, strain-specific neutralizing antibodies
elicited by GIII JEV vaccines in vaccine recipients need to be
assessed against GI virus. The protective efficacy of inactivated JE-
VAX (suckling mouse brain-derived Nakayama vaccine) and P3,
and live-attenuated SA14-14-2 vaccines has been evaluated in a
mouse model. Beasley et al. have shown that mice that received JE-
VAX vaccine or were passively transferred JE-VAX-vaccinated
mouse sera had lower neutralizing antibody titers and were less
protected against GI virus as compared to GIII virus, but the
strain-dependent protection could not be excluded [19]. However,
Liu et al. showed that the live-attenuated SA14-14-2 and
inactivated P3 vaccines protected vaccinated mice equally against
GIII and GI viruses [20]. In a series of ex vivo studies, Van Gessel et
al. eloquently demonstrated that mice receiving passively trans-
ferred immune sera collected from adult human volunteers
vaccinated with JE-VAX or SA14-14-2-derived IC51 (tissue
culture-derived inactivated) vaccine were protected against GIII
and GI viruses, and firmly established for the first time that the
strain-specific correlate of protection (PRNT50$10) could be
accurately estimated by measuring the reciprocal neutralizing
antibody titer at the time of viral challenge [21].
The cross-neutralization and protection elicited by GIII JEV
vaccines against GI viruses are not consistent in mouse models.
More importantly, no study has been conducted using vaccinated
children’s serum specimens collected from the general population.
In the present study, the panel of specimens collected from
children immunized with mouse brain-derived and formalin-
inactivated Nakayama vaccine in Taiwan were assembled and
used to assess the potency of neutralizing antibodies against the
vaccine strain, a GIII local human isolate, and a newly introduced
GI mosquito isolate.
Materials and Methods
Amino Acid Analysis
The nucleotide and amino acid sequences of JEV GI, GIII, and
Nakayama viruses were retrieved from GeneBank and analyzed
using BioEdit version 7.1.3 [16,22]. To localize the amino acid
substitutions, the protein structure of JEV E glycoprotein was
downloaded according to recent report [23] and analyzed by
Swiss-Pdb Viewer 3.7 structure analysis software. The antibody-
accessible amino acids should have at least a 35% surface
accessibility potential based on the result of structure analysis
[24]. In order to assess the impact of amino acid substitutions on
the impact of E protein, the stability calculation was performed for
all amino acid substitutions by using the Prediction of Proteins
Mutations Stability Changes server (http://babylone.ulb.ac.be/
popmusic/index.html).
Study Subject
In Taiwan, a compulsory vaccination program was implement-
ed in 1968 which utilizes mouse-brain derived and formalin-
inactivated Nakayama vaccine. Children receive an initial dose of
vaccine at one-and-one-half-years of age, and subsequent doses
two weeks later, one year later, and in the first grade of elementary
school. We also collected serum samples from children who
received varying numbers of doses of vaccine and at different time
post final booster vaccination.
Ethics Statement and Human Sera
All the serum samples used in this study were collected from an
already-existing collection in two hospitals, the Mennonite
Christian Hospital in Hulian and the Tungs’ Taichung Metro-
harbor Hospital in Taichung, in 2010 and were anonymized. For
serum sample collection, the clinical protocols were reviewed and
approved by the institutional review boards of these two hospitals
(10-03-007-ER and 99006). Serum was obtained from whole
blood after clotting at room temperature and then centrifuged at
3,000 rpm for 10 min. The aliquot of serum was stored at 220uC
until use.
Serological Assay
Five JEV strains were used in the serological assay, including:
the GIII, cluster III Nakayama vaccine strain; the GIII, cluster I
CJN strain isolated from human brain in 1998; the GIII, cluster II
T1P1 strain isolated from a mosquito pool in 1997 [15]; and the
GI, cluster I TC2009-1 strain and GI, cluster II YL2009-4 strain
isolated from mosquito pools in 2009 [16]. Viruses were amplified
in C6/36 mosquito cells and stored in aliquots at 280uC until use.
Plaque reduction neutralization tests (PRNT) are the most
suitable method for assessing neutralizing antibodies against JEV.
The PRNT protocol used is similar to that in our previous report
with some modification [17]. The BHK-21 cells were dispensed
into each well of 6-well polystyrene plates (Costar, Cambridge,
MA, USA). The plates were incubated at 37uC for 36 h to form a
monolayer. Serum samples were inactivated at 56uC for 30 min
before a two-fold serial dilution was carried out. A target dose of
about 100 plaque forming units (PFUs) of JEV were then
incubated with the previously diluted serum samples. The mixture
of diluted test serum and control virus was added onto the BHK-
21 monolayers. After adsorption for 1 h at 37uC, the infected cells
were overlaid with 4 ml/well of 1.1% methyl cellulose (Sigma) in
MEM containing 2% FBS and 1% antibiotics. After an additional
incubation for 3.5–4 days, the cells were fixed with 10% formalin
and stained with 1% crystal violet. The PRNT titer was obtained
from the reciprocal of the dilution of serum that reduced the
plaque number by at least 50% relative to the virus-only control.
To determine the potential for antibody-dependent enhance-
ment (ADE) of different genotypes of JEV, K562 cells were used to
measure viral yield and infection rate [25]. The undiluted serum
samples were used in the assay. Briefly, 100 ml serum was mixed
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due to genotype replacement should be closely monitored
in the JE epidemic/endemic regions in the future.
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with 26105 K562 cells and 26104 PFUs virus (MOI= 0.1), and
incubated with gentle rotation at 37uC for 2 h. After being washed
twice, the cells were incubated with RPMI-FBS medium at 37uC
for one day. The culture supernatants were collected and the viral
yield was determined by plaque count using BHK-21 cell
monolayers; also, infected K562 cells were collected, stained with
mouse anti-JEV HIAF, and the cell infection rate was estimated by
flow cytometry. The monoclonal antibody 4G2 (obtained from Dr.
Chang GJ of US CDC, Fort Collins, CO) was diluted 1:100 and
was used as the positive ADE control.
Statistics
A cut-off value to determine seropositivity of neutralizing
antibody titer was defined as PRNT50$10. Seropositive subjects
were defined as those having a reciprocal antibody titer above or
equal to the cut-off value; seronegative subjects, those falling below
the cut-off value. Antibody titers below the cut-off value of 1:10
were given an arbitrary value of 5 for geometric mean titer (GMT)
calculation.
The cut-off value for virus yield and cell infection rate for
differentiating neutralization and enhancement was calculated
from the average of five repeat measurements plus two times the
standard deviations (SD) of the viral yield and cell infection rate
obtained with the negative controls. In the negative controls,
RPMI-FBS was substituted for the serum specimen in the virus–
serum–cell preparation. Virus yield and cell infection rate of at
least 2SDs above the negative control was determined to represent
a statistically significant event.
Student’s t rest was used for all analyses, and statistical
significance was defined as a P value ,.05.
Results
Amino Acid Analysis
The GIII Nakayama strain has been used exclusively for the
manufacture of formalin-inactivated suckling mouse brain-derived
human vaccine in Taiwan since 1968. An extensive field
investigation and molecular epidemiological study outlined in
our previous report indicates that the replacement of JEV GIII by
GI occurred in 2009 in Taiwan [16]. JEV envelope (E) protein is
the primary antigen eliciting protectively neutralizing antibodies.
The amino acid differences in the E protein region between
Nakayama vaccine strain and GI and GIII sequences of virus
isolated from Taiwan are shown as Table S1. Amino acid
differences in the E protein between the vaccine strain and strains
used in this study are highlighted in Figure 1. There are eight
amino acid differences between Nakayama and the human brain
isolate GIII CJN virus, including E protein amino acid positions
33, 51, 83, 176, 227, 242, 276, and 290 (Figure 1). Among these
residues, position 33, 176, and 290 are located in E domain I
(EDI); 51, 83, 227, 242, and 276 are located in EDII; and none are
in EDIII. There are 13 amino acid variations between Nakayama
and mosquito isolate GI TC2009-1 virus, including E protein
amino acid positions 33, 51, 83, 123, 129, 176, 222, 227, 242, 276,
290, 327, and 366 (Figure 1). Among these residues, positions 33,
176, and 290 are located in EDI; 51, 83, 123, 129, 222, 227, 242,
and 276 are located in EDII; and 327 and 366 are located in
EDIII. The unique differences distinguish the CJN and GI strains
from the vaccine Nakayama strain were at E protein amino acid
positions 33, 51, 83, 176, 227, 242, 276, and 290.
Strain-Specific Neutralizing Antibody
A pilot experiment was conducted to determine the difference of
neutralizing antibody titers against five JEVs, GIII Nakayama
(cluster III), GIII T1P1 (cluster II), GIII CJN (cluster I), GI
TC2009-1 (cluster I), and GI YL2009-4 (cluster II), were evaluated
using the small panel of serum samples (Figure S1) [15,16]. The
correlation of PRNT50 between T1P1 and CJN or TC2009-1 and
YL2009-4 was 0.75 and 0.92 (Figure S1), respectively. Due to
insufficient amount of some serum samples, the GIII Nakayama,
GIII CJN, and GI TC2009-1 viruses were selected as viral strains
for further analysis.
A total of 157 serum samples from vaccinated children were
collected and grouped based on age (0–15 years) and dosage of
vaccination (0–4 doses) at the time of sampling (Table 1). The
seroprotection or seropositivity rate, defined by the PRNT50$10
using BHK-21 cells against homologous Nakayama strain, was
66.7% after primary vaccination, peaking after the receipt of the
4th dose of vaccine (80.0% for 8–9-years-old), but decreased
gradually to 60.0% in children aged 14–15 years (Figure 2). The
trend in strain-specific seroprotection rate against the GIII CJN
strain was similar to that of Nakayama virus, but the seroprotec-
tion rate themselves were generally lower (ranged from 0 to
21.5%) as compared to those for the Nakayama strain. The
seroprotection rate against GI TC2009-1 virus were much lower
as compared to other two viruses, especially in the 14–15-years-of-
age group (P,.05, Figure 2).
The geometric mean titers (GMT) of strain-specific PRNT50
against the GIII vaccine and CJN viruses and the TC2009-1 GI
virus are shown in Table 1. The GMT of neutralizing antibodies
against homologous Nakayama strain was 25.2 after primary
vaccination and reached a peak (38.0) following the third dose of
vaccine, but decreased gradually after the final booster and dipped
below the protective threshold of 10 in children aged 14–15 years.
The strain-specific GMT of neutralizing antibodies against the
GIII CJN strain trended similarly to those against the Nakayama
virus, but the titers were lower. Interestingly, the GMT of
antibodies neutralizing field-isolated GI TC2009-1 virus were
significantly lower than those for the other two viruses (P,.05) and
the titers were below the presumptive protective threshold of 10
with the exception of children aged 2.5–4 years who had received
a third dose of vaccine.
Protective Threshold for GI Virus
Neutralizing antibodies elicited by the mouse brain-derived,
formalin-inactivated Nakayama vaccine could be protective
against circulating GIII and GI virus in Taiwan (Figure 2 and
Table 1). Serum specimens capable of neutralizing Nakayama
virus were selected and stratified into groups with PRNT50 titers of
10, 20, 40, 80, 160, and §320. The strain-specific GMT from
each group was calculated for the human brain GIII CJN and
mosquito GI TC2009-1 viruses (Table 2). The grouping results
suggest that the GMT reach the presumptive protective threshold
(PRNT50= 10) against CJN and TC2009-1 viruses when the
neutralizing titer against Nakayama virus is 1:20 or 1:80,
respectively.
Potential of Antibody-Dependent Enhancement of
Infection
Antibodies elicited by the inactivated Nakayama vaccine are less
potent in neutralizing GI virus, and the majority of vaccinees’
PRNT50 titers are below the protective threshold (Table 2). The
enhancement of virus infection resulting from vaccination has
been suggested [26]. Thus, 26 serum samples from vaccinated
children were selected, and the undiluted serum samples were used
to estimate the potential for ADE of GI JEV infection in K562
cells by measurement of viral yield (Figure 3). The three serum
samples most highly neutralizing against Nakayama
Inactivated JEV Vaccine against GI Virus
PLOS Neglected Tropical Diseases | www.plosntds.org 3 September 2012 | Volume 6 | Issue 9 | e1834
(PRNT50§80) also strongly inhibited the infectivity of GI JEV. Of
the 16 weakly neutralizing serum samples (PRNT50= 10 to 40
against Nakayama), only three exhibited some increase in virus
yields as compared to the control serum. However, most (6/7) of
the non-neutralizing serum samples (PRNT50,10 against Na-
kayama) enhanced GI virus infection.
The risk of ADE of GI JEV infection in K562 cells was also
analyzed by flow cytometry to determine the infection rate of cells
infected with serum-treated virus. The results of selected samples,
not all samples were included due to insufficient amount individual
serum, are shown in Figure 4. At an MOI=0.1, the untreated
K562 infection rate by TC2009-1 was 6.9%. Thus, an infection
rate of less than 6.9% can be interpreted as neutralization, and
greater than 6.9% as enhancement. The flavivirus group-cross
reactive murine monoclonal antibody 4G2, used as an ADE
control at a 1:100 dilution, resulted in an infection rate of 20.5%,
significantly higher than that of the virus control. The T36
(PRNT50 = 20) and C86 (PRNT50= 160) samples neutralized GI
virus, and the cell infection rate were reduced to 1.4–1.5%,
significantly lower than that of the virus control (P,0.05). The
B19 serum neutralized Nakayama and CJN viruses, but not
TC2009-1 virus. Treatment with B19 serum resulted in some
degree of enhancement of TC2009-1 infection (10.5% infection)
(P..05). Sera I6, 113, D7, D15, and I5, non-neutralizing against
all three viruses, showed significant enhancement of GI JEV
infection (P,.05).
In addition, we conducted an ex vivo ADE experiment with
vaccinees serum samples, and the result was shown in Supple-
mental Figure 2. Due to the availability of vaccinee’s serum, the
undiluted serum from TC36, C86, D7, and I5 only were
preincubated with 1000 PFU of TC2009-1 virus and injected
intraperitoneally into suckling mouse (four mice per serum
sample). The brain of infected suckling mouse was collected at
four days post-inoculation; and the virus titer was determined by
the plaque forming assay in BHK21 cells. The TC36 and C86
serum samples almost completely neutralized TC2009-1 virus
replication in suckling mouse. However, compared to virus
control, the mouse brain virus titers were significantly increased
to 5.53- and 5.79-fold when the TC2009-1 virus was pre-
incubated with D7 or I5 serum samples, respectively. The result of
Figure 1. Structural locations of Japanese encephalitis virus (JEV) envelope (E) protein variations. Amino acid variations between the
Nakayama vaccine strain and the GIII brain-isolated CJN strain are indicated in blue, and variations between the Nakayama vaccine strain and the GI
field-isolated TC2009-1 strain are indicated in both blue and red.
doi:10.1371/journal.pntd.0001834.g001
Table 1. Geometric mean titers (GMT) of strain-specific neutralizing antibody against vaccine and field-isolated genotype III and I
viruses among serum samples collected from children immunized with inactivated JEV Nakayama vaccine.
Age (years) Sample size Vaccination (Dosage) PRNT50 GMT against virus (95% CI)
Nakayama CJN TC2009-1
0–1.5 13 0 5.9(4.2–8.3) 5.9(4.6–7.5) 5.6(4.4–7.0)
1.5–2.5 6 2 25.2(4.9–129.4) 8.9(4.4–18.2) 9.9(2.3–42.8)
2.5–4 14 3 38.0(15.5–93.0) 18.1(7.5–43.9) 15.6(7.1–34.5)
5–7 24 3 15.9(10.8–23.2) 12.6(8.8–18.1) 6.5(5.4–7.8)
8–9 40 4 13.9(10.8–17.9) 9.7(7.8–11.9)1 6.6(5.7–7.7)
10–11 20 4 16.8(10.1–28.1) 20.0(11.0–36.2) 8.1(5.7–11.5)
12–13 20 4 13.2(8.6–20.2) 12.3(8.3–18.3) 5.9(5.0–7.1)
14–15 20 4 9.3(6.9–12.5) 7.3(5.9–9.1) 5.4(4.8–5.9)
1Boldface indicates titers significantly different (P,.05) from those for Nakayama virus by pairwise comparisons.
doi:10.1371/journal.pntd.0001834.t001
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this ex vivo ADE experiment was consisted with the result of flow
analysis (Figure 4).
Discussion
Long-term evolution, geographical barriers and host-parasite
interactions have resulted in many flaviviruses evolving into
multiple genotypes, including dengue virus serotypes 1 through 4,
West Nile virus, and JEV [27,28,29,30,31,32]. Genotype replace-
ment in dengue virus serotypes 3 and 4 in Sri Lanka and Puerto
Rico, respectively, has resulted in increased transmissibility and
epidemic potential of the new viruses [33,34]. Vaccination is the
most effective strategy to control flavivirus epidemics [35].
Genotype I JEV has replaced GIII as the dominant genotype
throughout Asian countries, and human clinical cases due to GI
virus infection have been observed in China [10,36]. The GIII
mouse brain-derived, inactivated Nakayama vaccine and live-
attenuated SA14-14-2 vaccine are the most widely distributed
Table 2. Strain-specific protection threshold of inactivated Nakayama Japanese encephalitis virus vaccine.
PRNT50 against Nakayama Sample size
PRNT50 GMT against virus (95% CI)
CJN TC2009-1
10 37 9.09 (7.8–10.64) 5.28 (4.97–5.65)
20 34 15.01 (12.02–18.75) 6.63 (5.74–7.7)
40 18 20.76 (13.46–31.92) 9.25 (7.34–11.69)
80 6 31.71 (6.61–151.36) 11.21 (5.50–22.91)
160 3 63.41 (1.77–2243.88) 31.71 (4.36–229.61)
§320 4 67.22 (4.24–1066.60) 113.00 (59.43–211.84)
doi:10.1371/journal.pntd.0001834.t002
Figure 2. The seropositivity rate of children immunized with inactivated Nakayama JEV vaccine against JEVs. Seropositivity is defined
by a reciprocal titer of$10 in a 50% plaque-reduction neutralization test using BHK-21 cells. Significantly different (P,.05) seropositivity rates against
CJN or TC2009-1 as compared to that for Nakayama virus are indicated by asterisks.
doi:10.1371/journal.pntd.0001834.g002
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vaccines in Asian countries, including Japan, Korea, Taiwan,
Vietnam, Thailand, Malaysia, China, India, and Nepal [3,4]. The
replacement of GIII by GI virus provides the opportunity to
evaluate the contribution of genotype replacement to the strain-
specific vaccine effectiveness of JEV. The reported protective
efficacies of GIII JEV vaccines against GI virus are not consistent
due to differences in evaluation models used, including virus strain,
passive or active immunization, and challenge dosage (17, 18, 19).
The Nakayama JEV was isolated in 1935, and the vaccine
derived from it was developed in 1956 [37]. Differences between
vaccine strain and circulating GIII viruses are expected, but the
vaccine is proven to be highly protective [38]. The efficacy of
formalin-inactivated Nakayama JEV vaccine in vaccinees who
received one, two, and three doses of immunization is 85.59%,
91.07% and 98.51%, respectively [8]. The trial of mouse brain-
derived inactivated JEV vaccine, including Nakayama or Na-
kayama plus Beijing-1 strains, was conducted in Thailand in
1984–1985, and the estimated efficacy was 91%. But, several JE-
confirmed cases were diagnosed among vaccinated group indicat-
ing the potential of primary vaccine failure. The JEV genotype I
was first isolated in the Southeast Asian countries; it has been
suggested that the switch from genotype III to I in the 1980s might
contribute to the primary vaccine failure without confirmed
virological evidence [13,39]. Our study also showed that the
vaccine, used in Taiwan, offered strain-specific neutralization
against field-isolated GIII CJN virus. This result suggests and
supports that the amino acid variations, located in EDI and EDII,
between these two viruses, are not critical in eliciting neutralizing
antibody as compared to residues located in domain III [40].
Our previous report demonstrated GI JEV replaced GIII in
Taiwan in 2009, and here we conducted the first study using
serum samples from vaccinated children to systematically evaluate
strain-specific neutralizing antibodies elicited by the GIII Na-
kayama vaccine [16]. Previous report indicated that the GMT
titers against GIII isolates, including T1P1, CC27, CJN, and
CH1392, were 2-fold lower than that against Nakayama strain;
and Shyu et al., reported that only 37.9% of vaccinees sera in the
15–19 year-old group can actually neutralize JE5 Taiwanese
isolate [17,18]. In presented study, the neutralizing titer against GI
virus was 8-fold lower (Table 2) than against Nakayama strain, and
the seroprotection threshold against GI virus was 10% of vaccinees
in the vaccinated 14–15 year-old group. Thus, the lower titers of
antibody against GI in general in Taiwan might relate directly to
overall antigenic variability between GIII and GI, but strain-
dependent neutralization could not be totally excluded. The
seroprotection rate should be appropriately estimated against
currently circulating JE strains rather than against vaccine strain.
There were only five informative amino acids variations
between GIII and GI JEV in the E protein: residues 123, 129,
222, 327, and 366. However, the antibodies elicited by the GIII
JEV vaccines were only weakly neutralizing against circulating GI
virus as compared to the human GIII isolate. Three of the five
amino acid differences occur in domain II, which is involved in
weakly or non-neutralizing antibody binding [41], and residues
129 and 222 are not accessible for antibody binding. Thus, the
remaining two amino acid variations, residues 327 and 366, might
play an important role in lower strain-specific neutralization
against GI virus as compared to the GIII vaccine and human
isolates. These two residues are accessible for antibody binding
and are located in domain III of the E protein, which has been
shown to be the most important region eliciting neutralizing
antibody. Antibodies targeting domain III of E protein make up a
Figure 3. Effects of children’s undiluted serum samples on viral yield of GI JEV from K562 cells. The magnitude of enhancement of viral
yield is calculated as follows: Log10 (serum-treated viral titer/untreated viral titer). The K562 cells infected with labeled samples C86, TC36, B19, D7,
D15, 113, I5 and I6, were subjected to infection rate analysis by flow cytometry (Figure 4).
doi:10.1371/journal.pntd.0001834.g003
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relatively small proportion of the polyclonal human antibody
response against flaviviruses, thus more detail studies are need to
clarity the role of residues 327 and 366 [42].
GI virus-specific residues at position 327 and 366 located in the
BC and DE loops on domain III of E protein, respectively, may
play an important role in eliciting genotype-specific neutralizing
antibodies. Genotype- and strain-specific neutralizing MAbs have
been characterized against dengue virus serotypes 1, 2 and 3 [36–
38]. Monoclonal antibody E104, derived from mice immunized
with GII of DENV-1 virus, is a genotype-specific MAb, which
recognizes residues 328, 330, 361 and 362 in the BC and DE loops
of EDIII. Residues 328 and 329, located in the BC loop, are
recognized by another DENV-3-derived genotype-specific MAb.
Thus, the amino acids located in the BC and DE loops on domain
III of E protein may involve in the induction of genotype-specific
neutralizing antibodies.
Non-neutralizing antibodies are a possible risk factor for ADE in
dengue pathogenesis during infection with heterologous or
homologous dengue viruses, but the role of ADE contributes to
JE disease is unclear [43]. Vaccine-induced enhancements of virus
infection have been documented for members of different virus
families as well [26]. Our preliminary in vitro and ex vivo studies
suggest that the potential of ADE with vaccinees serum specimens
may be increased due to GIII to GI replacement. Prior to the
genotype replacement in Taiwan, the average mortality rate of
confirmed cases of JEV infection was 7.8% (2000–2008).
However, during 2009–2010, after GI JEV became the dominant
circulating virus, the average mortality rate increased to 14.2%
(Official statistics of the Department of Health, Taiwan). The
neurovirulence of GI and GIII viruses was similar and might not
directly associate with an increasing case fatality rate of JE cases
[19,20]. The potential for ADE, measured by in vitro assays and
supplemented by the limited number of ex vivo assays, increases
dramatically when the neutralization titer of vaccinee serum
decreases to below the protective threshold of 1:10 against the
vaccine strain. The statistical differences we have seen in older
children, reflecting waning of neutralizing antibody to GI virus to
less than seroprotective threshold (Figure 2). The presence of
memory B cells, CD4+ and CD8+ T cells, and anamnestic
response has been indicated after received JEV inactivated vaccine
[44], but rapidly decline of seroprotection rate against field-
isolated JEVs also has been suggested [45]. Thus, the duration of
immunity among vaccinated adults should be evaluated compre-
hensively ten years after the final booster vaccination.
The conclusion of current study is limited by the small sample
size and the volume of vaccinee’s serum. With the Institution
Approved Protocol in the further, we plan to increase the sample
size and collect larger serum volume to increase more selection of
GIII and GI strains in the analysis. The most cost-effective control
strategy for JE is vaccination, but genotype replacement in JEV
endemic/epidemic regions may reduce the efficacy of traditional
GIII virus-based vaccines. The efficacy of GIII JEV vaccines
should be closely monitored at the national or regional level. The
potential impact due to genotype replacement could be overcome
in the future by 1) increasing the effective immunogenic dose or
incorporating a novel adjuvant in the vaccine formulation to
improve the immunogenicity of the current vaccine, or 2)
replacing the GIII vaccine strain with a dominant GI isolate and
Figure 4. Patterns of ADE in K562 cells infected by virus treated with serum samples. The virus control is GI TC2009-1 virus-infected K562
cells in the absence of serum samples. The ADE of TC2009-1 virus in K562 cells by using 1:100 diluted 4G2 monoclonal antibody as a positive ADE
control and the serum samples collected from vaccinated children including C86, TC36, B19, I6, 113, D7, D15, and I5. The K562 cells were collected,
stained with mouse anti-JEV HIAF, and analyzed for infection rate by flow cytometry.
doi:10.1371/journal.pntd.0001834.g004
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conducting a non-inferiority study of GI strain-specific immune
responses.
Supporting Information
Figure S1 Selection of JEVs for neutralizing antibody
assay. Four JEVs, GIII T1P1 (cluster II), GIII CJN (cluster I), GI
TC2009-1 (cluster I), and GI YL2009-4 (cluster II), were evaluated
using a panel of serum samples (N= 10 and 15 for panel A and B,
respectively) by a plaque-reduction neutralization assay. The
correlations of PRNT50 were determined between (A) T1P1 and
CJN or (B) TC2009-1 and YL2009-4. Number in black circle
corresponding to the specimen number.
(TIF)
Figure S2 Semi-ex vivo ADE experiment. The undiluted
serum was pre-incubated with 1000 PFU of TC2009-1 virus and
inoculated intraperitoneally into four suckling mice per serum.
Brains of inoculated sucking mice were harvested and virus titers
determined by plaque forming assay in BHK-21 cells.
(TIF)
Table S1 Amino acid variations among JEV E protein
between genotype and cluster.
(DOC)
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